Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLCOT-T2D
NCT05633810Phase 3Recruiting
- Sponsor
- Montréal Heart Institute
- Start
- Dec 2022
- Primary completion
- Dec 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of colchicine and aspirin in type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) (4 arms), sponsored by Montréal Heart Institute. Primary endpoint: First event of the composite of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, or urgent hospitalization for angina requiring coronary… at 60 months. Started Dec 2022; status: recruiting.
02
Drugs
colchicineaspirin
03
Conditions
type 2 diabetes mellitus (T2DM)cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT05633810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05633810.